Drug Development · global
Dazodalibep shows efficacy in Phase 3 Sjögren’s disease trial, improving disease activity and dryness
A 648-patient trial shows that blocking CD40L signaling can reduce systemic disease activity in Sjögren’s disease, with dosing every four weeks also improving patient-reported dryness. The findings add evidence for a disease with limited treatment options, but long-term benefits and safety remain to be clarified.
The burden of Sjögren’s disease often extends beyond dry eyes and dry mouth; fatigue, joint pain, and involvement of the lungs, kidneys, or nervous system can all affect patients’ lives. On November 11, Amgen released details from a Phase 3 trial of its investigational drug dazodalibep, showing that both dosing regimens reduced systemic disease activity, while dosing every four weeks also improved patient-reported dryness. The findings add treatment evidence for a disease that currently has no specifically approved drug from the U.S. Food and Drug Administration (FDA).
The announcement coincided with presentation LB22 at the American College of Rheumatology’s ACR Convergence 2026 meeting, following positive topline results announced in September. However, the main efficacy figures and dryness scores had already been disclosed in a pre-meeting announcement on October 27, rather than being revealed for the first time in November. The latest details further covered different degrees of disease improvement, salivary secretion, and safety observations.
OASIZ-301 was a randomized, double-blind, placebo-controlled trial involving 648 patients with moderate to severe systemic disease activity. The study assessed disease activity using ESSDAI, with participants having a mean baseline score of 10.2. After 48 weeks of treatment, scores decreased by an average of 5.6 points in the group receiving 1,500 mg of dazodalibep every four weeks, 5.2 points in the group receiving 3,000 mg every 12 weeks, and 3.8 points in the placebo group. The two regimens produced improvements of 1.8 and 1.4 points beyond placebo, respectively, both statistically significant, although the results also showed substantial improvement in the placebo group itself.
Patients’ everyday experiences provide another perspective on the findings. In the group dosed every four weeks, the ESSPRI dryness domain score decreased by 2.50 points, compared with 1.33 points in the placebo group. For another measure, the DASPRI dryness domain, the respective decreases were 1.98 and 1.05 points. Adjusted p-values for both comparisons were less than 0.001. These data support the regimen’s effect on dryness, but do not allow a direct inference that dosing every 12 weeks provides the same degree of symptom benefit. The company also reported a greater increase in stimulated salivary flow among patients receiving the drug, but the announcement did not specify the magnitude.
Dazodalibep is a CD40L-antagonist fusion protein designed to disrupt immune signaling among T cells, B cells, glandular epithelial cells, and other antigen-presenting cells. In Sjögren’s disease, this development approach aims to intervene in immune activation, affecting both systemic disease manifestations and gland-related symptoms. However, these 48-week results cannot yet answer whether improved scores translate into long-term organ protection.
On safety, both Amgen’s announcement and reporting by BioPharm International indicated that serious adverse events, treatment discontinuations due to adverse events, and malignancies were broadly comparable across groups, with no imbalance in thromboembolic events between groups. Adverse events occurring more frequently in the drug groups included nasopharyngitis, urinary tract infections, hypertension, and infusion-related reactions, most of which were mild to moderate. These observations help assess current risks, but cannot rule out rarer problems or those that may emerge only with longer-term use.
The significance of this study lies in its evidence addressing both disease activity and patient symptoms. However, the data currently come primarily from company announcements and conference reporting, and complete study data are still needed to assess more closely which patients are most likely to benefit, how the magnitude of improvement is distributed, and how long efficacy can be sustained. Dazodalibep remains an investigational therapy, and meeting Phase 3 endpoints still leaves hurdles, including regulatory review, before it can become an available treatment option.